EXTON, Pa. and GERMANTOWN, Md., Jan. 13, 2014 /PRNewswire/ -- Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for skin diseases and conditions with high unmet medical needs, and Intrexon Corporation (NYSE: XON), a leader in synthetic biology, announced today an expansion of their Exclusive Channel Collaboration (ECC) to develop a treatment for Ehlers-Danlos syndrome hypermobility type (EDS-HT), a rare genetic disorder resulting in weakened connective tissue.
Fibrocell and Intrexon will endeavor to engineer autologous fibroblast cells genetically corrected to produce tenascin-X (TN-X), a protein that is deficient in the connective tissue of a subset of EDS-HT patients. Patients with EDS-HT often experience significant musculoskeletal complications, including frequent joint dislocations, subluxations and early onset osteoarthritis.
Jouni Uitto, M.D., Ph.D., Chair of the Department of Dermatology and Cutaneous Biology at Thomas Jefferson University in Philadelphia, Pennsylvania, said the collaboration is a step toward addressing the unmet needs of EDS patients around the world.
"There are currently no therapies for hypermobility-type EDS," said Dr. Uitto. "Healthcare providers are only able to treat the severe symptoms of EDS, such as prescribing braces to improve joint stability and by assisting patients with the pain they experience. The prospect of an actual treatment is wonderful news for these patients."
Fibrocell Chief Executive Officer David Pernock noted that the companies' evolving expertise and experience gained through the existing R
|SOURCE Intrexon Corporation|
Copyright©2012 PR Newswire.
All rights reserved